Trial reportBMC cardiovascular disorders2026
One-year outcomes of a novel balloon-expandable valve for severe aortic stenosis.
Trial report in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study evaluated the safety and efficacy of the Renatus transcatheter aortic valve system in treating severe aortic stenosis.
methodsThis prospective, multicenter, single-arm clinical trial employed a target-value approach. The primary endpoint was the all-cause mortality rate at one year postoperatively, while secondary endpoints included assessments of safety and effectiveness. Safety was measured by the all-cause mortality rate at 30 days, the incidence of major adverse cardiovascular events within one year, and the device success rate. Effectiveness was assessed using transvalvular pressure gradient measurements, the incidence of paravalvular leaks, improvements in New York Heart Association (NYHA) cardiac function classification, and quality of life assessments.
resultsThe study enrolled 166 patients across 14 national centers between July 2021 and April 2022, with a mean age of 73.9 ± 6.0 years and a median STS risk score of 7.7% (IQR 4.1–8.8). Notably, 58.4% of participants had a bicuspid aortic valve (BAV). Baseline comparisons revealed that BAV patients were marginally younger than tricuspid aortic valve (TAV) patients (median age 73 [IQR 69–77] vs. 74 [IQR 71–79], p = 0.055), with larger annular diameters, greater calcification, and more transverse aortic anatomy. All-cause mortality rates at 30 days and one year postoperatively were 2.5% and 3.7%, while cardiac mortality rates were 1.8% and 3.0%, respectively. Rates of permanent pacemaker implantation at 30 days and one year were 1.8% and 3.0%, respectively. Moderate-to-severe paravalvular leaks were present in 2.5% of patients at 30 days, increasing to 6.6% after one year. Stroke, coronary obstruction, and myocardial infarction incidences remained low, at 0.6%. EuroQol-5 Dimension scores significantly improved from 67.7 ± 18.4 at baseline to 80.0 ± 11.6 and 83.7 ± 10.1 at 30 days and one year, respectively. Patients with NYHA classes I and II rose dramatically from 18.7% at baseline to 99.3% postoperatively.
conclusionAmong selected patients, the Renatus balloon-expandable transcatheter valve system was associated with favorable safety and efficacy outcomes at 1-year post-procedure, regardless of aortic valve leaflet morphology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.